What pandemic? Biotech floats break records
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Added firepower could signal a spending spree for Sanofi
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
TG pulls victory from the jaws of defeat
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
G1 makes the most of trilaciclib's unclear survival benefit
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
